Marketable Securities |
Marketable Securities At March 31, 2017, marketable securities consisted of the following (in thousands): | | | | | | | | | | | | | | | | | | Amortized Cost | | Unrealized Gains | | Unrealized Losses | | Aggregate Fair Value | U.S. treasury debt securities | $ | 3,502 |
| | $ | — |
| | $ | (6 | ) | | $ | 3,496 |
| U.S. corporate debt securities | 9,003 |
| | 3 |
| | (4 | ) | | 9,002 |
| Money market funds | 45,230 |
| | — |
| | — |
| | 45,230 |
| | $ | 57,735 |
| | $ | 3 |
| | $ | (10 | ) | | $ | 57,728 |
| Included in cash and cash equivalents | $ | 45,230 |
| | $ | — |
| | $ | — |
| | $ | 45,230 |
| Included in marketable securities | $ | 12,505 |
| | $ | 3 |
| | $ | (10 | ) | | $ | 12,498 |
|
At December 31, 2016, marketable securities consisted of the following (in thousands): | | | | | | | | | | | | | | | | | | Amortized Cost | | Unrealized Gains | | Unrealized Losses | | Aggregate Fair Value | U.S. treasury debt securities | $ | 3,503 |
| | $ | — |
| | $ | (5 | ) | | $ | 3,498 |
| U.S. corporate debt securities | 7,943 |
| | 1 |
| | (7 | ) | | 7,937 |
| Money market funds | 43,496 |
| | — |
| | — |
| | 43,496 |
| | $ | 54,942 |
| | $ | 1 |
| | $ | (12 | ) | | $ | 54,931 |
| Included in cash and cash equivalents | $ | 43,496 |
| | $ | — |
| | $ | — |
| | $ | 43,496 |
| Included in marketable securities | $ | 11,446 |
| | $ | 1 |
| | $ | (12 | ) | | $ | 11,435 |
|
The following table presents gross unrealized losses and fair values for those marketable securities that were in an unrealized loss position as of March 31, 2017, aggregated by investment category and the length of time that individual securities have been in a continuous loss position (in thousands): | | | | | | | | | | | | | | | | | | As of March 31, 2017 | | Less than 12 months | | 12 months or greater | | Fair Value | | Unrealized Loss | | Fair Value | | Unrealized Loss | U.S. treasury debt securities | $ | 3,496 |
| | $ | (6 | ) | | $ | — |
| | $ | — |
| U.S. corporate debt securities | 5,036 |
| | (4 | ) | | — |
| | — |
| Total | $ | 8,532 |
| | $ | (10 | ) | | $ | — |
| | $ | — |
|
We do not believe any of the unrealized losses represented an other-than-temporary impairment based on our evaluation of available evidence, which includes our intent as of March 31, 2017 to hold these investments until the cost basis is recovered.
|